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RESUMO
É comum considerar ambíguo como sinô-
nimo de confuso. Em uma informação con-
fusa, várias informações têm um mesmo
significado. Na informação ambígua, ao
contrário, vários significados são atribuídos
a uma mesma palavra. Informações exces-
sivas também geram ambiguidade, daí a
necessidade de concisão e clareza na lin-
guagem. O termo evento adverso (EA) é
definido como qualquer ocorrência médi-
ca inconveniente, sofrida por um sujeito da
pesquisa em investigação clínica. A confu-
são e a ambiguidade no uso de palavras
podem gerar conseqüências importantes
na valorização de EAs. O objetivo deste es-
tudo, de natureza teórica, é harmonizar o
vocabulário utilizado na caracterização dos
riscos e na comunicação de EAs na pesqui-
sa clínica. Os EAs podem ser classificados
quanto à previsibilidade, frequência, gra-
vidade, causalidade e seriedade. Muitas
vezes, em documentos regulatórios, os EAs
são definidos em função da seriedade e
causalidade. A harmonização do vocabulá-
rio na comunicação de EAs é fundamental
para evitar a utilização equivocada de pa-
lavras com sentido confuso, ou ambíguo.
DESCRITORES
Pesquisa biomédica.
Ética em pesquisa.
Bioética.
Sujeitos da pesquisa.
ABSTRACT
It is quite common to consider the terms
ambiguous and confusing as synonyms.
Confusing information brings together vari-
ous data with similar meanings. In ambigu-
ous information, on the other hand, several
meanings are assigned to a single word.
Excessive information also generates am-
biguity; therefore, a concise, clear language
is demanded. The term adverse event (AE)
is defined as any inconvenient medical oc-
currence suffered by a subject during a clini-
cal investigation research. Confusion and
ambiguity in the use of words may gener-
ate relevant consequences in the appraisal
of AEs. The objective of this present theo-
retical study is to harmonize the vocabu-
lary applied in the characterization of risks
and in the communication of AEs in clinical
research processes. AEs may be classified
according to their predictability, frequency,
gravity, causality, and severity. Regulatory
documents usually address AEs in their se-
verity and causality aspects. Vocabulary
conformity in the communication of AEs is
an essential step towards avoiding inaccu-
rate use of words with confused or ambigu-
ous meanings.
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RESUMEN
Es común considerar ambiguo como siendo
sinónimo de confuso. En una información
confusa, varias informaciones tienen un mis-
mo significado. En la información ambigua,
al contrario, varios significados son atribui-
dos a una misma palabra. Informaciones ex-
cesivas también generan ambigüedad, por
esa razón es necesario ser conciso y claro en
el lenguaje. El término evento adverso (EA)
es definido como cualquier ocurrencia mé-
dica inconveniente, sufrida por un sujeto par-
ticipante del estudio, en investigación clíni-
ca. La confusión y la ambigüedad en el uso
de las palabras pueden generar consecuen-
cias importantes en la valorización de los EAs.
El objetivo de este estudio, de naturaleza
teórica, es armonizar el vocabulario utiliza-
do en la caracterización de los riesgos y en la
comunicación de los EAs en la investigación
clínica. Los EAs pueden ser clasificados en
cuanto a su previsibilidad, frecuencia, gra-
vedad, causalidad y seriedad. Muchas veces,
en documentos normativos, los EAs son de-
finidos en función de la seriedad y causa-
lidad. La armonización del vocabulario en la
comunicación de EAs es fundamental para
evitar la utilización equivocada de palabras
con sentido confuso, o ambiguo.
DESCRIPTORES
Investigación biomédica.
Ética en investigación.
Bioética.
Sujetos de investigación.
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INTRODUCTION
Good Clinical Practice (GCP) guidelines are interna-
tional scientific and ethical quality standards for the de-
velopment, conduct, recording and reporting of health
research involving human subjects. Compliance helps to
ensure the protection of human rights of participants in a
clinical trial(1). A Research Ethics Committee (REC) evalu-
ates and follows research projects(2). The process of evalu-
ating adverse events (AEs) helps to establish risk/benefit
ratio. In project implementation and follow-up activities,
monitoring AEs is crucial.
In 1993, the International Ethical Guidelines for Research
Involving Human Beings were published by the Council for
International Organizations of Medical Sciences (CIOMS)(3),
associated to the World Health Organization (WHO). In
2002(4), they were reviewed. In 1996, in Brazil, the National
Council of Health (NCH) Resolution 196/96 established, in
item V.4, that the
Research Ethics Committee of the institution should be
informed of all AEs, or relevant facts that can alter the nor-
mal course of the study(2).
The NCH Resolution 251/97 on research regulations for
new drugs, medications, vaccines and diagnosis tests, im-
plies (item III.2.d) that the responsible researcher must re-
port to REC any events of AEs and /or unwelcome adverse
reactions(5).
One of the limitations regarding the evaluation and fol-
low-up of AEs is the exact meaning of these terms. Inap-
propriate use generates ambiguity and confusion. The lack
of concise language and understanding damage evaluations
and reports of AEs in clinical research. The aim of this work
is to harmonize the vocabulary used in describing these risks
and reporting of AEs in clinical research.
CONFUSION AND AMBIGUITY
Ambiguity is the obscurity of the meaning in words and
phrases. Also, it carries a sense of hesitation, doubt and
indecision between two or more possibilities, and even
multiple meanings(6). Ambiguous is commonly considered
a synonym for confusing. In confusing information, differ-
ent information has the same meaning. In contrast, with
ambiguous information, many different meanings are at-
tributed to a single word. Excessive information also leads
to ambiguity. Therefore, the need for concision and clarity
of ideas in language work is imperative.
The term AEs is defined as any inconvenient medical
occurrence, experienced by one of the research’s subjects
or individual under clinical investigation. Confusion and
ambiguity in the use of words can lead to important conse-
quences in the importance of AEs. AEs can be classified as
for their predictability, frequency, intensity, attribution, and
seriousness
AE intensity is classified as mild, moderate, serious, or
lethal(7). Different authors confuse this classification with a
serious adverse event (SAE). They are classified according
to the consequences resulting from such event. An SAE
implies death, hospitalization, prolonged hospitalization,
or any other relevant consequence to the medical point of
view; including persistent or significant deficiency/incapac-
ity, and congenital/defect(1). The term serious is frequently
used to describe the intensity of a specific event (as in a
mild, moderate or serious myocardial infarction); however,
the event itself can have a relatively smaller clinical mean-
ing (as serious headache). It does not mean the same as
serious, which is based on the consequence of the event;
or in action criteria commonly associated to events that
are life threatening or represent a threat to the patient’s
life. Therefore, a serious-intensity AE (serious nausea) can
occur not demonstrating any relation applied to the SAE
term, low-repercussion clinical event, namely non-serious.
However, a moderate-intensity AE resulting in hospitaliza-
tion is considered as SAE
ADVERSE EVENTS
AEs, defined as unintentional complications resulting from
the care provided, are acknowledged as one of the most im-
portant problems in the health area(8). An AE is any unwel-
come medical occurrence during a treatment with a phar-
maceutical product, however not necessarily presenting a
causing relation to the treatment(9). As for a change in the
study focus that evolved from a medical legal feature into
studies on quality improvement, the AE was then defined as
an unintentional injury resulting in a temporary or perma-
nent incapacity and/or prolonging the stay period or pre-
senting death as a consequence of the care provided(10). For
example, any allergic episode is an AE. If a patient using a
certain drug presents an allergy, it does not imply that it is
resulting from the use of the drug. Another identifying fac-
tor, not related to the medication, can be the generating fac-
tor. However, the health professional should not include,
beforehand, that an allergy is resulting from this factor(11).
After finding the AE, the cause-effect relation must be inves-
tigated between the allergy and the medication.
An AE can be any inconvenient medical event experi-
enced by a research subject or individual under clinical in-
vestigation with pharmaceutical products that does not
necessarily presents a causing relation with this treatment.
It can be an unfavorable and unintentional sign, symptom
or temporary disease associated to the use of a medical
product under investigation; whether or not related to this
product(1).
A SAE is any unwelcomed medical occurrence, under
any prescribed dose that: results in death; represents a life
risk; requires hospitalization of the research subject, or pro-
logues a pre-occurring hospitalization; results in significant
or persistent incapacitation/incapacity; causes congenital
defect/anomaly(1).
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The unexpected adverse reaction to a drug is a natural
reaction or intensity non-consistent to the applicable infor-
mation of the mentioned product (example: Investigator’s
Brochure for the product under investigation, not yet ap-
proved), or instruction/summary of pharmaceutical char-
acteristics for approved products(1).
When a medication or drug is administrated in a study,
apart from the useful therapeutic effects, in some people, some
unwanted effects are also observed. There are no adverse re-
action risk-free drugs. The probability of occurrence can vary,
the reaction can be mild, or serious, perhaps predictable or
not, however, the doctor/researcher and the research patient/
subject should always be aware of this possibility.
Classification of adverse effects (AEs)
Regarding AEs, they can be classified as for their pre-
dictability, frequency, intensity, attribution, and seriousness
(Table 1).
Mild
Short Duration
Neither requires
medication nor treatment
suspension.
Not causing or
lingering hospitalization
WHO
Defined
Probable
Possible
NARANJO
Defined
Probable
Possible
Severe
Potentially lethal
Hospitalization or the
lingering of it.
Medication suspension
Specific treatment
Lethal
Life-threatening
Very rare
< 0,01%
Rare
> 0,01% and
< 0,1%
Very common
> 10%
SeriousnessCausalityIntensityPredictability
Improbable
Conditional
Unclassifiable
Classifiable
Unlikely or
Unrelated
ADVERSE EVENTS
Before After
Not quantified
Chance
Moderate
Therapeutic modification
No need for suspending
medication
May cause or linger
hospitalization
Requires specific treatment
Frequency
Not serious
Serious
Lingering of
hospitalization
Hospitalization
Death
Other
Not common
> 0,1% and
< 1%
Common
> 1% and
< 10%
Predictable
Already reported
in other studies
Unpredictable
Unknown
(Uncertainty)
Table 1 - Classification of Adverse Effects - Porto Alegre - 2007
Adverse effects as for predictability
Regarding predictability, the AEs are those already de-
scribed in literature, in the product’s description, in the
investigator’s manual, or in the study protocol. Unpredicted
AE is the one not yet described, including events that may
be symptomatically and physic-pathologically related to
another one already described, but different from this event
due to their gravity and specificity degree.
Adverse events as for frequency
Regarding frequency, AE are considered as: very com-
mon, when frequency is higher or equal to 10.00%; com-
mon, higher or equal to 1.00% and lower than 10.00%;
uncommon, higher or equal to 0.10% and lower than 1.00%;
rare, higher or equal to 0.01% and lower than 0.10%; very
rare, lower than 0.01%(12).
Adverse events as for intensity
AEs as for their intensity are classified as mild, moder-
ate, serious, or lethal(7), according to their intensity and the
verified events.
The intensity of adverse alterations in physical signs or
symptoms will be regarded as: mild, of short term, not re-
quiring specific treatment neither medication suspension,
there is neither the need for antidotes nor for hospitaliza-
tion; moderate, altering patient’s normal activities, requir-
ing medication therapy changes, despite not being neces-
sary to suspend the causing drug, they can cause or pro-
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long hospitalization and require specific treatment; serious,
are potentially lethal, requiring interruption of the drugs
and the specific treatment, they require hospitalization or
prolonging patient’s stay in the hospital; lethal, they directly
or indirectly cause the death of the patient(7).
The WHO also considers four categories of intensity: 1)
mild: little importance reactions and short active period,
they may require treatment, but they do not substantially
affect patients’ normal life course; 2) moderate: alter pa-
tients’ normal activities, resulting in transitory incapacity
with no sequels, causing hospitalization, prolonging hospi-
tal stay, urgency care and service, absence at work or school;
3) serious: reactions directly threatening patients’ life, con-
genital anomalies, resulting in permanent or significant in-
capacity, or needing intervention to avoid sequels; 4) le-
thal: reactions that lead to the death of the patient(13).
Adverse events as for attribution
Regarding attribution, an AE can be associated to the
performed intervention – cause/effect retrospective rela-
tion – classified as follows: definite, probable, possible, or
unlikely or unrelated(7). However, the WHO considers the
following attribution categories: definite, probable, pos-
sible, improbable, conditional (unclassified) and
unclassifiable (not accessible), depending on the security
level of the cause-effect relation(14).
Definite: clinical event, including abnormalities in labo-
ratorial tests, occurring within plausible time in relation to
the administration of the medication and that cannot be
explained by the base disease or by other medication or
even chemical substances. The response to suspending the
use of this medication must be clinically plausible. The event
must be pharmacologic, or resulting from a definite phe-
nomenon, using a satisfying re-introduction procedure, if
needed(14).
Probable: clinical event, including abnormalities in labo-
ratory tests occurring under a reasonable administration
period for the medication that cannot probably be attrib-
uted to a concomitant disease or other medication, chemi-
cal substances and that present a reasonable clinical re-
sponse to the suspension of this medication. Re-introduc-
tion information is not needed to complete this definition(14).
Possible: clinical event, including abnormalities in labo-
ratory tests occurring under a reasonable administration
period for the medication, however they can also be ex-
plained by a concomitant disease or other medication or
chemical substances. Information on the interruption of the
medication can be absent or obscure(14).
Improbable: clinical event including abnormalities in
laboratory tests that present a transitory relation to the
administration of a medication; causing an improbable
causing relation and that in other medication, chemical
substances or subjacent diseases, propitiate plausible
explanations(14).
Conditional/unclassified: clinical event, including abnor-
malities in laboratory tests, notified as an AE, where more
data is needed for an appropriate evaluation, or when ad-
ditional data are being analyzed(14).
Unclassifiable/non-accessible: Notification suggesting
an AE that cannot be evaluated, since information is not
sufficient or contradictory and that cannot be completed
or verified(14).
The WHO segments unlikely or unrelated attribution
into improbable, conditional, or unclassifiable. Thus, attri-
bution can be characterized by six categories: definite, prob-
able, possible, improbable, conditional and unclassifiable(14).
Adverse events as for seriousness
Seriousness classification comprises serious and non-
serious AEs. They are classified due to the consequences
resulting from such event. A serious AE results in death,
hospitalization, prolonging hospital stay or other relevant
consequences under the medical point of view(1). Accord-
ing to the Collegiate Board Resolution RDC 339 of June 5,
2008, in item X, SAEs are defined as those resulting on any
adverse experience with drugs, or biologic products or de-
vices, occurring within any dose and that result in any one
of the following: death, potentially lethal AE (an effect that
sets the patient under immediate death risk due to the oc-
curred AE); persistent or significant incapacity/disability;
requiring hospitalization or prolonging pre-existing hospi-
tal stay; congenital anomaly or birth defect(15). A non-seri-
ous AE is any AE that does not fulfills the criteria of a SAE.
RESEARCH ON NEW DRUGS:
ASSOCIATED RISKS
The clinical phase of the research with new medication
contains four phases, I to IV, depending on the knowledge
level presented on these drugs’ effects in cellular, animal
and human models. Specific objectives from each type of
study are used; the type of outline, the number of partici-
pants, and their characteristics. Phases are successive and
scaled with increasing complexity and exposition levels(16).
The NCH Resolution 251/97(5) incorporates the decisions
in the NCH Resolution 196/96(2) on Guidelines and Regulat-
ing Norms for the Research Involving Human Beings, which
is a complementary part of the research area with new
drugs, medication, vaccines and diagnosis tests.
Phase I studies are carried out on small groups of volun-
teers, generally healthy, of a new active principle or formula-
tion. Depending on the specialty and objective of the research,
Phase I studies can be carried out directly on specific groups
as carriers of irreversible chronicle diseases as oncology, psy-
chiatric disorders or altered kidney function patients(5-17).
Studies on Phase II are pilot therapeutic studies to dem-
onstrate the activity of establishing short term safety of
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the active principle in patients affected by a specific dis-
ease or pathologic condition. They are carried out on a lim-
ited number of participants and frequently followed by an
administrative study with a view to establish the dose-re-
sponse relation(5). Phase IIa and IIb comprise dose titling
and efficiency.
Initial Phase II studies (phase IIa) use drug doses already
tested as safe on Phase I studies. They regard studies aimed
at evaluating the tolerability and safety of these new drugs(18).
Samples are small and follow rigid control measures(17).
Phase II advanced studies (phase IIb) are conducted on
larger samples with well defined inclusion criteria. They
have the objective of adding data related to the drug’s effi-
ciency(18). Even with a short period of follow up, the occur-
rence of some AEs can be verified.
Phase III studies are amplified therapeutic studies car-
ried out in large, varied groups of patients. They aim at de-
termining the short and long term risk/benefit results of
active principle formulations, and, generally their therapeu-
tic value. With a view to establish and approve the pre-
sumed benefit. In this phase, the most frequent adverse
reactions type of profile is explored as well as the medica-
tion special characteristics(5).
Phase III studies were recently subdivided into phases
IIIa and IIIb. The purpose of the first phase is to evaluate
the efficiency of drugs already tested in Phase I and II stud-
ies. Phase IIIb studies are carried out while the application
for registration of a new drug is being issued. The phase
increases the observation period for medication effects(18).
Continuous clinical monitoring of phase III studies is
needed for providing an appropriate follow up of the pro-
cess of recruiting and selecting participants, and also the
credibility and quality of data, research subjects follow up
and AEs evaluation. This is especially relevant for SAEs since
they involve prolonging hospital stay, the need for hospi-
talization, or the death of the participant.
If the product is within acceptable toxicity standards, it
is approved. However, since the number of patients in phase
III rarely reach more than ten thousand, it is still difficult to
establish adverse incidence lower than 1:20.000(11).
Phase IV studies are researches with a view to monitor-
ing, or post-selling vigilance of the drug. They aim at estab-
lishing the therapeutic value, on large scale, and the ap-
pearance of new adverse reactions, as the less frequent
reactions and/or the confirmation for those already known
and treatment strategies(5).
According to item I.4 of NCH Resolution 251/97(5),
in any clinical testing, and specifically in conflicts of interests
involving new products’ research, the dignity and well-being
of the subject included in the research must prevail over
other interests, whether economic, scientific or pertaining
to the community.
According to national and international resolutions, ev-
ery research project on new drugs, involving human be-
ings, must be subjected to REC and must be followed by
the Free and Informed Consent Form (FICF) and the
researcher’s manual. The manual, also known as the
investigator’s brochure, comprises information on pharma-
cokinetic and pharmacy dynamics data of the drug under
study, toxicity studies, previously performed clinical stud-
ies (for instance, the same drug in other countries), pre-
dicted AEs; in other words, it comprises pre-clinical tests
and clinical tests already carried out with this drug.
The project, researcher manual and the FICF must show,
appropriately described, the AEs reported in clinical stud-
ies with the drug under investigation, allowing for knowl-
edge and decision making by the subject regarding the par-
ticipation in the research.
Researches on new drugs require attention both for the
predicted risks evaluation and for monitoring AEs during
project execution.
Two important and complementary stages are; risk
evaluation and monitoring of AEs. The evaluation consists
of verifying the predicted risks in the beginning of the re-
search, whether in the Free and Informed Consent Form
(FICF), in the project or in the investigator’s manual. Moni-
toring happens through AEs reporting. They will be attached
to the research, contributing for the dynamic decision mak-
ing process. In case risks are higher than benefits, REC can
re-evaluate the project, with a view to the participants’
safety.
As the project is executed, the current AEs appear. Risk
evaluation precedes this moment and allows for verifying
if that AE was reported, and therefore, is predictable or, in
case it was not reported, it stands uncertain. Already re-
ported AEs can be classified according to frequency as very
common, common, not common, rare and very rare(12). Also,
the intensity association, according to the intensity of the
event, can be mild, moderate, serious or lethal(7). However,
monitoring occurs as the execution of the project, allowing
for the classification of the event as for its attribution, based
on the cause/effect retrospective relation, establishing the
causing association between the drug and the occurring
AEs under the following proposed categories by the WHO:
definite, probable, possible, improbable, conditional and
unclassifiable(14). Based on the consequence/result, this
event can be classified according to its severity as; non-se-
rious, serious causing prolonging hospitalization, hospital-
ization, death, other significant event form the medical
point of view(1) (Figure 1).
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CURRENT ADVERSE
EFFECT
Attribution
Retrospective relation
Cause effect
- definite
- probable
- possible
- improbable
- conditional
- non-classifiable
Severity
(consequence)
- not serious
- serious: prolonging hospitalization,
hospitalization, death or other
significant event from the medical
point of view.
NOT REPORTED
Uncertainty
FUTURE
RISK EVALUATION
AEs ALREADY REPORTED
Predictability
Frequency
- very common
- common
- not-common
- rare
- very rare
Gravidade ou Severidade
(Intensity)
- lethal
- severe
- moderate
- mild
MONITORING
PAST
PROJECT
It is worth mentioning that risk evaluation is considered
as those AEs predicted and quantified. In other words, that
presents occurrences probability. AEs described and not-
quantified are uncertain, where they can only present as-
sociated chances not considered as risks but as associated
damages. Yet unpredicted AEs are unknown as for the be-
ginning of the project.
In scientific research projects, we cannot dismiss the
inherent risks: real, predicted and the unpredicted. Pre-
dicted risks are the known expected risks, already observed
in similar projects, including in clinical testing using the same
drug; they must be in the investigator’s manual, in the
project and in the FICF stating their probabilities and oc-
currence risks. Real risk is the AEs that occur. Unpredicted
risk is an unexpected damage that occurs afterwards; some-
thing that was not expected and happened in reality. In the
case where the real risk exceeds the predicted risk, the
project must be reviewed.
Figure 1 - Relation between time and adverse event - Porto Alegre - 2007
CONCLUSION
Classification of AEs for predictability, frequency, and
intensity are based on previous studies (preliminary stud-
ies and clinical phases I, II and III) with the experimental
drug. However, AE classification regarding attribution and
seriousness occurs afterwards, since they can only be clas-
sified throughout the execution of the project.
In most cases, even in regulatory documents, AEs are de-
fined due to their seriousness and attribution. The importance
of harmonizing the vocabulary in reporting AEs is crucial to
avoid the erroneous use of confusing and ambiguous words.
Ambiguous information must be avoided, regarding
more than one meaning that leads to lack of understand-
ing, confusion, imprecision and lack of clarity. AE risk evalu-
ation, as well as reporting and monitoring AEs, requires
appropriate language so that authors and researchers them-
selves can understand them; if not, evaluation and moni-
toring activities can be damaged.
REFERENCES
1. European Medicines Agency. Guideline for good clinical
practice. London; 2002.
2. Conselho Nacional de Saúde. Resolução n. 196, de 10 de outu-
bro de 1996. Dispõe sobre diretrizes e normas regulamentado-
ras de pesquisas envolvendo seres humanos. Bioética. 1996;4(2
Supl):15-25.
3. World Health Organization (WHO). Council for International
Organizations of Medical Sciences. International ethical
guidelines for biomedical research involving human subjects.
Geneva; 1993.
689Rev Esc Enferm USP2009; 43(3):683-9www.ee.usp.br/reeusp/
Confusions and ambiguities in the classification
of adverse events in the clinical research
Marodin G, Goldim JR
4. World Health Organization (WHO). Council for International
Organizations of Medical Sciences. International ethical
guidelines for biomedical research involving human subjects.
Geneva; 2002.
5. Conselho Nacional de Saúde. Resolução n. 251, de 7 de agosto
de 1997. Dispõe sobre normas de pesquisas com novos
fármacos, medicamentos, vacinas e testes diagnósticos envol-
vendo seres humanos [legislação na Internet]. Porto Alegre:
Bioética; 2007 [citado 2008 jan 16]. Disponível em: http://
www.ufrgs.br/bioetica/res25197.htm
6. Houaiss A, Villar MS. Dicionário Houaiss da língua portuguesa.
Rio de Janeiro: Objetiva; 2001.
7. Naranjo CA, Busto U. Reações adversas às drogas. In: Kalant H,
Roschlau WHE. Princípios de farmacologia médica. Rio de Ja-
neiro: Guanabara Koogan; 1991. p. 537-42.
8. Gallotti RMD. Eventos adversos e óbitos hospitalares em servi-
ço de emergências clínicas de um hospital universitário
terciário: um olhar para a qualidade da atenção [tese]. São Pau-
lo: Faculdade de Medicina, Universidade de São Paulo; 2003.
9. Edwards R, Biriell C. Harmonization in pharmacovigilance. Drug
Saf. 1994;10(2):93-102.
10. Mendes W, Travassos C, Martins M, Noronha JC. Revisão dos
estudos de avaliação da ocorrência de eventos adversos em
hospitais. Rev Bras Epidemiol. 2005;8(4):393-406.
11. Zanini AC, Carvalho MF. Definições, conceitos e aspectos
operacionais utilizados em farmacovigilância. Rev Bras Cienc
Farm. 2001;37(3):215-24.
12. World Health Organization (WHO). Council for International
Organizations of Medical Sciences. Guidelines for preparing
core clinical safety information on drug from CIOMS Working
Group III. Geneva; 1995.
13. Dias MF, Tolentino M, Figueiredo PM, Vila-Inda CJ, Leite EL,
Queiroz F, et al. Notificações de suspeitas de reação adversa a
medicamento para Unidade de Farmacovigilância ANVISA no
primeiro semestre de 2002. In: Anais do 1° Simpósio Brasileiro
de Vigilância Sanitária; 2002 dez. 2-4; São Paulo, BR [evento na
Internet]. Brasília: ANVISA; 2002 [citado 2007 out. 10]. Dispo-
nível em: http://www.anvisa.gov.br/farmacovigilancia/traba-
lhos /posters/simbravisa_3.pdf
14. Organização Mundial da Saúde (OMS). Monitorização da se-
gurança de medicamentos: diretrizes para criação e funcio-
namento de um Centro de Farmacovigilância. Brasília; 2005.
15. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sa-
nitária. Resolução RDC n. 39, de 5 de junho de 2008. Aprova o
Regulamento para a Realização de Pesquisa Clínica e dá outras
providências [legislação na Internet]. Brasília; 2008. [citado 2008
jun. 6]. Disponível em: http://e-legis.anvisa.gov.br/leisref/
public/showAct.php?mode=PRINT_VERSION&id=31279
16. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N,
Newman TB. Delineando a pesquisa clínica. Porto Alegre:
Artmed; 2006.
17. United States. Code of Federal Regulations. 21 CFR. Food and
drugs. 312.21 Phases of an Investigation. Washington; 2003.
18. Goldim JR. A Avaliação ética da investigação científica de no-
vas drogas: a importância da caracterização adequada das fa-
ses da pesquisa. Rev HCPA. 2007;27(1):66-73.
Financing/Support:
FIPE/HCPA and CAPES.
rrespondence addre sed to: Gabriela Marodin
Rua Cel. Joaquim Pedro Salgado, 267 - Ap. 701, Bairro Rio Branco
CEP 90420-060 - Porto Alegre, RS, Brazil
